Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Crispr Therapeutics Ag
(NQ:
CRSP
)
45.51
-0.07 (-0.15%)
Streaming Delayed Price
Updated: 10:24 AM EDT, Oct 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Crispr Therapeutics Ag
< Previous
1
2
...
12
13
14
15
16
17
18
19
20
...
29
30
Next >
What 17 Analyst Ratings Have To Say About CRISPR Therapeutics
June 09, 2023
Via
Benzinga
TGT Stock Alert: Have Target’s Sales Numbers Peaked?
June 09, 2023
Target (TGT) stock is in hot water on Friday after Citi analyst Paul Lejuez warned investors to stay away from the retailer.
Via
InvestorPlace
Why Is CRISPR Therapeutics (CRSP) Stock Moving Today?
June 09, 2023
CRISPR Therapeutics (CRSP) stock is on the move Friday after the company revealed data from its CLIMB-111 and CLIMB-121 clinical trials.
Via
InvestorPlace
Crispr Stock Slips; The FDA Could Approve The First CRISPR-Based Gene-Editing Drug In Just Six Months
June 09, 2023
The agency said it will make an approval decision on Crispr's exa-cel in December.
Via
Investor's Business Daily
Wall Street Loves These 3 Growth Stocks -- Should You?
June 09, 2023
Analysts think all three of these stocks could soar.
Via
The Motley Fool
Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress
June 09, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Can This Gene-Editing Stock Deliver 10X Returns?
June 08, 2023
Buying shares of Intellia Therapeutics might be a smart move.
Via
The Motley Fool
FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
June 08, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
June 08, 2023
Today, CRISPR has reached an important turning point.
Via
The Motley Fool
Cathie Wood Is Buying the SEC Lawsuit Dip in Coinbase (COIN) Stock
June 07, 2023
Coinbase and the crypto industry at large is at war with regulators. But Cathie Wood is still buying shares of COIN stock.
Via
InvestorPlace
Why Are Gene Editing Stocks EDIT, NVTA, CRSP Up Today?
June 06, 2023
Gene editing stocks are up today on news that Editas Medicine will present clinical data on June 12. Here's what this means for the sector.
Via
InvestorPlace
CRISPR Therapeutics: A Galaxy's Worth of Deep Value
May 31, 2023
Wall Street is at max pessimism with this biotech, which might be a big mistake.
Via
The Motley Fool
3 Disruptors I Love Right Now
May 30, 2023
These stocks could deliver huge returns as the companies transform the economy.
Via
The Motley Fool
CRISPR Therapeutics Earnings Perspective: Return On Capital Employed
May 23, 2023
Via
Benzinga
3 Top Healthcare Stocks to Buy for June
June 06, 2023
These stocks have what it takes to deliver long-term growth.
Via
The Motley Fool
Prediction: These 2 Stocks Could Double In the Next Year
May 28, 2023
It would be a continuation of solid recent performances.
Via
The Motley Fool
3 No-Brainer Stocks to Buy for Under $100 Right Now
May 27, 2023
These stocks might not remain under $100 for too much longer.
Via
The Motley Fool
2 Supercharged Stocks to Buy With $100
May 27, 2023
These stocks are climbing in the double digits.
Via
The Motley Fool
2 Top Trends to Invest $5,000 in Right Now
May 25, 2023
Renewable energy and gene-editing medical therapies are poised to grow exponentially.
Via
The Motley Fool
Better Growth Stock: CRISPR Therapeutics vs. Teladoc Health
May 25, 2023
Both stocks are recovering after big losses last year.
Via
The Motley Fool
Analyst Expectations for CRISPR Therapeutics's Future
May 23, 2023
Via
Benzinga
Is CRISPR Therapeutics Stock a Buy Now?
May 13, 2023
The clinical-stage biotech company has been on the rise.
Via
The Motley Fool
A Good Week For The Market But A Pause In The Biotech Rally
May 22, 2023
Healthcare stocks have been lagging in 2023 with the XLV down 1.97% MTD and 3.34% YTD with CVS and UNH contributing to the weakness.
Via
Talk Markets
Cathie Wood Just Sold CRISPR Therapeutics Stock. Here's Why You Should Consider Buying It
May 21, 2023
Her investing thesis for holding it is probably the same as ever.
Via
The Motley Fool
Cathie Wood Is Buying This Biotech Stock Like Wildfire, But Should You?
May 21, 2023
It's facing a few issues that are practically guaranteed to affect shareholder returns.
Via
The Motley Fool
3 Biotech Stocks That Are Revolutionizing Healthcare in 2023
May 19, 2023
Here are three of the best biotech stocks to buy; each is on the verge of significant breakthroughs that may send the price higher.
Via
InvestorPlace
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings
May 18, 2023
Vertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets.
Via
MarketBeat
Exposures
Product Safety
2 Stocks You'll Be Glad You Bought at These Prices
May 17, 2023
Bear markets create opportunities to buy high-growth stocks at discounted valuations.
Via
The Motley Fool
2 Soaring Growth Stocks That Could Rocket Even Higher
May 16, 2023
One of these stocks is up 57% this year, and the other one has more than tripled already.
Via
The Motley Fool
Why These 3 Nasdaq Stocks Were Glowing Green This Week
May 11, 2023
These three biopharmaceutical stocks rocketed higher this week.
Via
The Motley Fool
< Previous
1
2
...
12
13
14
15
16
17
18
19
20
...
29
30
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.